Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 231

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases

Chan, Nancy, Willis, Amy, Kornhauser, Naomi, Ward, Maureen M., Lee, Sharrell B., Nackos, Eleni, Seo, Bo Ri, Chuang, Ellen, Cigler, Tessa, Moore, Anne, Donovan, Diana, Vallee Cobham, Marta, Fitzpatrick, Veronica, Schneider, Sarah, Wiener, Alysia, Guillaume-Abraham, Jessica, Aljom, Elnaz, Zelkowitz, Richard, Warren, J. David, Lane, Maureen E., Fischbach, Claudia, Mittal, Vivek, Vahdat, Linda · 2017 · Clinical Cancer Research

Abstract

Purpose: Bone marrow–derived progenitor cells, including VEGFR2+ endothelial progenitor cells (EPCs) and copper-dependent pathways, model the tumor microenvironment. We hypothesized that copper depletion using tetrathiomolybdate would reduce EPCs in high risk for patients with breast cancer who have relapsed. We investigated the effect of tetrathiomolybdate on the tumor microenvironment in preclinical models. Experimental Design: Patients with stage II triple-negative breast cancer (TNBC), stage III and stage IV without any evidence of disease (NED), received oral tetrathiomolybdate to maintain ceruloplasmin (Cp) between 8 and 17 mg/dL for 2 years or until relapse. Endpoints were effect on EPCs and other biomarkers, safety, event-free (EFS), and overall survival (OS). For laboratory studies, MDA-LM2-luciferase cells were implanted into CB17-SCID mice and treated with tetrathiomolybdate or water. Tumor progression was quantified by bioluminescence imaging (BLI), copper depletion status by Cp oxidase levels, lysyl oxidase (LOX) activity by ELISA, and collagen deposition. Results: Seventy-five patients enrolled; 51 patients completed 2 years (1,396 cycles). Most common grade 3/4 toxicity was neutropenia (3.7%). Lower Cp levels correlated with reduced EPCs (P = 0.002) and LOXL-2 (P < 0.001). Two-year EFS for patients with stage II–III and stage IV NED was 91% and 67%, respectively. For patients with TNBC, EFS was 90% (adjuvant patients) and 69% (stage IV NED patients) at a median follow-up of 6.3 years, respectively. In preclinical models, tetrathiomolybdate decreased metastases to lungs (P = 0.04), LOX activity (P = 0.03), and collagen crosslinking (P = 0.012). Conclusions: Tetrathiomolybdate is safe, well tolerated, and affects copper-dependent components of the tumor microenvironment. Biomarker-driven clinical trials in high risk for patients with recurrent breast cancer are warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1326

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 6 references

Cited by

See all 231

Metadata

Authors
Chan, N., Willis, A., Kornhauser, N., Ward, M. M., Lee, S. B., Nackos, E., Seo, B. R., Chuang, E., Cigler, T., Moore, A., Donovan, D., Vallee Cobham, M., Fitzpatrick, V., Schneider, S., Wiener, A., Guillaume-Abraham, J., Aljom, E., Zelkowitz, R., Warren, J. D., Lane, M. E., Fischbach, C., Mittal, V., & Vahdat, L.
Venue
Clinical Cancer Research
Published
2017-01-31
Volume
23
Issue
3
Pages
666-676
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2532243786
Cited by
231
References
6
FWCI
11.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1326
The paper
Chan, N., Willis, A., Kornhauser, N., Ward, M. M., Lee, S. B., Nackos, E., Seo, B. R., Chuang, E., Cigler, T., Moore, A., Donovan, D., Vallee Cobham, M., Fitzpatrick, V., Schneider, S., Wiener, A., Guillaume-Abraham, J., Aljom, E., Zelkowitz, R., Warren, J. D., . . . Vahdat, L. (2017). Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung Metastases. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1326

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.